Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.
| Image |  |
|---|---|
| Description | scientific article published in February 2018 |
| Author/s |
author: Chrysanthi Sardeli |
| Publication date | February 1, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |